State Street Corp Raises Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

State Street Corp lifted its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 8.3% during the 3rd quarter, Holdings Channel reports. The firm owned 4,703,442 shares of the company’s stock after buying an additional 359,685 shares during the period. State Street Corp owned approximately 0.05% of Myriad Genetics worth $128,827,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in MYGN. Point72 Hong Kong Ltd acquired a new stake in Myriad Genetics during the 3rd quarter worth approximately $32,000. Innealta Capital LLC acquired a new position in shares of Myriad Genetics in the second quarter valued at approximately $36,000. GAMMA Investing LLC raised its stake in shares of Myriad Genetics by 34.1% during the third quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock worth $44,000 after purchasing an additional 412 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Myriad Genetics during the second quarter worth $60,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Myriad Genetics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock worth $87,000 after purchasing an additional 583 shares during the period. Hedge funds and other institutional investors own 99.02% of the company’s stock.

Myriad Genetics Trading Down 0.5 %

Shares of MYGN stock opened at $14.43 on Friday. The stock has a market cap of $1.31 billion, a P/E ratio of -11.10 and a beta of 1.87. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a fifty-two week low of $13.92 and a fifty-two week high of $29.30. The business has a fifty day simple moving average of $18.82 and a 200-day simple moving average of $23.57.

Insider Buying and Selling at Myriad Genetics

In related news, CEO Paul J. Diaz sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, October 11th. The stock was sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now owns 962,378 shares of the company’s stock, valued at approximately $22,067,327.54. This represents a 1.53 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on MYGN shares. Bank of America cut their price objective on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating for the company in a research report on Friday. Morgan Stanley cut their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. Leerink Partners cut Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $30.00 to $21.00 in a research report on Monday, December 9th. StockNews.com downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Leerink Partnrs downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $24.27.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.